Filling the Void: PAT in a Connected Manufacturing Environment

Neway,Justin;

Filling the Void: PAT in a Connected Manufacturing Environment

October 2, 2003

By Justin Neway

Publication

Article

Pharmaceutical TechnologyPharmaceutical Technology-10-02-2003

Volume 27

Issue 10

The author brings attention to the connectivity problems among various data-gathering systems and discusses the drivers and benefits of change, including PAT.

External Link - article-72839.pdf

Articles in this issue

Designing a New Drug Package

GMP Update: Reducing Obstacles to Innovation

Reducing the Time to Develop and Manufacture Formulations for First Oral Dose in Humans

Filling the Void: PAT in a Connected Manufacturing Environment

Process Analytical Technology Concepts and Principles

October 2003

Outsourcing is Front Page News in 2003

October 2003

In the Spotlight - November

Related Content

Sterile capsules for injection. Bottles on the bottling line of the pharmaceutical plant. Machine after checking sterile liquids. Interferon, nasoferon. | Image Credit: © neznamov1984 - stock.adobe.com

ten23 health Joins Gerresheimer, SCHOTT, Stevanato Group in ‘Alliance for RTU’

Patrick Lavery

July 1st 2025

Article

The partnership was formed in September 2024 in response to increasing demand for aseptic filling technologies and processes.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas

June 25th 2024

Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Aenova Adds Cold Chain Warehouse to Latina, Italy Site

Susan Haigney

June 27th 2025

Article

The new building expands on the company’s supply chain solutions for biologics and temperature-sensitive pharmaceuticals.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

April 30th 2024

Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.